Forian Analyst Ratings
Roth MKM Maintains Forian(FORA.US) With Buy Rating, Maintains Target Price $5
Forian (FORA) Receives a Buy From Roth MKM
Roth MKM Maintains Forian(FORA.US) With Buy Rating, Maintains Target Price $5
Forian (FORA) Receives a Buy From Roth MKM
Forian Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Forian (FORA), Achieve Life Sciences (ACHV) and P3 Health Partners (PIII)
Lake Street Sticks to Its Buy Rating for Forian (FORA)
Roth MKM Initiates Coverage On Forian With Buy Rating, Announces Price Target of $5
Forian Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Mirati Therapeutics (MRTX) and Forian (FORA)
Lake Street Sticks to Its Buy Rating for Forian (FORA)
Forian (FORA) Gets a Buy From Lake Street
Forian Analyst Ratings
Lake Street Reaffirms Their Buy Rating on Forian (FORA)
National Bank Revises VerticalScope's Price Target, Rating; Resets Forecast Amid Ad Pressure, E-Commerce Challenges
Lake Street Sticks to Their Buy Rating for Forian (FORA)
National Bank Cuts Price Target on VerticalScope Holdings Following Q4 Results
National Bank Cuts Top-Line Estimate on VerticalScope Holdings, Cuts Price Target; Down 12.6%
Forian Analyst Ratings
No Data